Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.

Viruses - 7 Apr 2021

Kim Yeong Jun, Jang Ui Soon, Soh Sandrine M, Lee Joo-Youn, Lee Hye-Ra

Abstract excerpt

A new variant of SARS-CoV-2 B.1.351 lineage (first found in South Africa) has been raising global concern due to its harboring of multiple mutations in the spike that potentially increase transmissibility and yield resistance to neutralizing antibodies. We here tested infectivity and neutralization efficiency of SARS-CoV-2 spike pseudoviruses bearing particular mutations of the receptor-binding domain (RBD)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Antibodies, Viral

Share to Molecular Dynamics Simulation

Share to South Africa

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 33917138
DOI: 10.3390/v13040633
PMCID: PMC8067879

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.PMID 33917138Read ↗

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.Semantic proximity Read ↗

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.Semantic proximity Read ↗

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodiesSemantic proximity Read ↗

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionSemantic proximity Read ↗

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.Semantic proximity Read ↗

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.Semantic proximity Read ↗

The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.Semantic proximity Read ↗

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429Semantic proximity Read ↗

Are the original SARS-CoV-2 novel mutants from in vitro culture able to escape the immune response?Semantic proximity Read ↗

Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies.Semantic proximity Read ↗

SARS-CoV-2 variants B.1.351 and B.1.1.248: Escape from therapeutic antibodies and antibodies induced by infection and vaccinationSemantic proximity Read ↗

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.